JOURNAL ARTICLE

Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience.

  • Published In: Journal of Oncology Pharmacy Practice, 2026, v. 32, n. 2. P. 229 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Deng, Weishang; Yang, Sensen; Yang, Changyuan; Chen, Haitao; Huang, Guoning; Wu, Hanbiao; Chen, Jisheng 3 of 3

Abstract

This article focuses on a real-world retrospective study comparing HLX01, the first rituximab biosimilar produced and marketed in China, with the original rituximab drug MabThera® in treating diffuse large B-cell lymphoma (DLBCL). The study found no significant differences between HLX01 and MabThera in overall response rate, complete response rate, progression-free survival, or safety profiles among 33 patients treated at a single Chinese hospital. Despite some baseline differences between patient groups and a small sample size, the findings support HLX01 as a clinically equivalent and more affordable alternative to MabThera for DLBCL treatment in China. The authors note that larger, multicenter real-world studies are needed to further validate these results and to assess HLX01's efficacy in other indications such as follicular lymphoma.

Additional Information

  • Source:Journal of Oncology Pharmacy Practice. 2026/03, Vol. 32, Issue 2, p229
  • Document Type:Article
  • Subject Area:Consumer Health
  • Publication Date:2026
  • ISSN:1078-1552
  • DOI:10.1177/10781552221110470
  • Accession Number:192502914
  • Copyright Statement:Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.